Gossamer Bio, Inc. (GOSS) stock
GOSSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$11.04+0.06 (+0.55%)
Close on Nov 17, 2026Market cap $5.40BP/E –Yield –
Gossamer Bio total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Gossamer Bio's total debt was $0 at Dec 31, 2024. For fiscal 2024 it was $0, down 100.0% from the year before. The highest annual figure on record is $29.08M in fiscal 2021.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | -100.0% |
| FY2023 | Dec 31, 2023 | $12.43M | -47.3% |
| FY2022 | Dec 31, 2022 | $23.60M | -18.8% |
| FY2021 | Dec 31, 2021 | $29.08M | +1.2% |
| FY2020 | Dec 31, 2020 | $28.74M | +1.0% |
| FY2019 | Dec 31, 2019 | $28.46M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $9.59M | -54.0% |
| Q4 FY2023 | Dec 31, 2023 | $12.43M | -47.3% |
| Q3 FY2023 | Sep 30, 2023 | $15.25M | -42.3% |
| Q2 FY2023 | Jun 30, 2023 | $18.05M | -38.3% |
| Q1 FY2023 | Mar 31, 2023 | $20.83M | -28.6% |
| Q4 FY2022 | Dec 31, 2022 | $23.60M | -18.8% |
| Q3 FY2022 | Sep 30, 2022 | $26.45M | -8.8% |
| Q2 FY2022 | Jun 30, 2022 | $29.26M | +1.2% |
| Q1 FY2022 | Mar 31, 2022 | $29.17M | +1.2% |
| Q4 FY2021 | Dec 31, 2021 | $29.08M | +1.2% |
| Q3 FY2021 | Sep 30, 2021 | $28.99M | +1.1% |
| Q2 FY2021 | Jun 30, 2021 | $28.91M | +0.9% |
| Q1 FY2021 | Mar 31, 2021 | $28.82M | +1.0% |
| Q4 FY2020 | Dec 31, 2020 | $28.74M | +1.0% |
| Q3 FY2020 | Sep 30, 2020 | $28.67M | +1.0% |
| Q2 FY2020 | Jun 30, 2020 | $28.64M | +1.3% |
| Q1 FY2020 | Mar 31, 2020 | $28.55M | – |
| Q4 FY2019 | Dec 31, 2019 | $28.46M | – |
| Q3 FY2019 | Sep 30, 2019 | $28.37M | – |
| Q2 FY2019 | Jun 30, 2019 | $28.28M | – |
See a number that looks wrong?